# The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD)

> **NCT00444912** · PHASE2 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 30 (actual)

## Conditions studied

- Non-Hodgkin Lymphoma
- Hodgkin Disease

## Interventions

- **DRUG:** G-CSF plus plerixafor
- **DRUG:** G-CSF plus plerixafor
- **BIOLOGICAL:** rituximab

## Key facts

- **NCT ID:** NCT00444912
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2014-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00444912

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00444912, "The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00444912. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*